translocation associated membrane protein 1Genealiases: PNAS8 · TRAM · TRAMP
Q-omics provides the consensus-scored TRAM1 profile across patient tissues and cancer cell-line models. TRAM1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRAM1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TRAM1 protein abundance shows 23,074 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where TRAM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAM1 survival associations across molecular data types. TRAM1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAM1 RNA expression–survival associations across cancer types. High TRAM1 expression shows unfavorable associations in UVM, KIRP, CESC, HNSC, BLCA and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRAM1 RNA expression.
This table summarizes TRAM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TRAM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAM1 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, BLCA, LIHC and KIRP. The HNSC box plot shows higher TRAM1 RNA expression in tumor versus normal tissue (log2 FC = +1.258, t-test p < 0.001).
This table shows molecular features associated with TRAM1 in patient tissues and cancer cell lines. In patient samples, TRAM1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
